Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the use of magnesium sulfate nebulization in patient with moderate to severe asthma exacerbation in pediatric emergency.

Detailed Description
-----------------
the use of magnesium sulfate nebulization in patient with moderate to severe asthma exacerbation in pediatric emergency follow asthma severity score and length of stay

Official Title
-----------------
Nebulized Magnesium Sulfate in Children With Moderate to Severe Asthma Exacerbation: A Randomized, Double-Blind, Controlled Trial (RCT)

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Magnesium Sulfate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pediatric asthma patients with moderate to severe exacerbation Exclusion Criteria: Known allergy to magnesium sulfate History of neuromuscular disease, cardiac disease, renal disease, or underlying chronic lung disease Use of oral steroid medication within 72 hours of presentation Radiographic evidence of pneumonia at presentation Administration of intravenous magnesium sulfate prior to study enrollment

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: magnesium sulfate arm<br>magnesium sulfate with standard therapy | Drug: Magnesium Sulfate<br>* single dose of magnesium sulfate nebulization<br>|
| No Intervention: placebo arm<br>placebo with standard therapy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma significantly reduce the time to clinical readiness for discharge? |  | 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| • Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma decrease admission and readmission rate, compared to placebo | Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma decrease PICU admission rate, compared to placebo? Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma improve change in asthma severity score at 4, 8, 12 hours, compared to placebo? Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma decrease return rate to emergency services, compared to placebo? Would the use of nebulized magnesium sulfate in patients with moderate to severe asthma decrease rate of infirmray admission in follow up, compared to placebo? | 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
magnesium, nebulization, asthma, sulfate, children, pediatric